From June 21 to June 22, the "Shanghai Biopharmaceutical Enterprises Going to Seas Training Course"，hosted by the Shanghai Biopharmaceutical Industry Promotion Center, organized by DIA (Shanghai) Information Technology Co. LTD., and guided by the Shanghai Scientific Commission, was a complete success. The positive academic atmosphere fully demonstrating the participants' strong interest in and urgent need for the expansion of the international pharmaceutical market.
Experts Gather to Discuss Internationalization Strategies
The Seminar invited numerous industry experts to jointly explore how Chinese innovative drugs can better enter the international market. Dr. Sun Hualong, Chief Strategy Officer of Clinical Service Center, was invited to serve as the conference chair. His professional insights and extensive experience added significant value to the conference, receiving unanimous praise from the attendees.
The in-depth discussion of these topics provided attendees with valuable experience and practical guidance.
In-Depth Topics Fully Covering Key Points of Innovative Drug Global Expansion
The training seminar covered several important themes, thoroughly exploring the critical aspects of bringing innovative drugs to the international market. These topics included:
-Strategies and regulatory requirements for global simultaneous registration
-International cooperation with clinical research institutions for innovative drugs
-The importance of executing overseas projects for innovative drugs
-How preclinical data such as CMC can meet the requirements of regulatory agencies in Europe and the United States
-R&D strategies and clinical trial designs to meet the needs of simultaneous domestic and international registration
-Overseas market layout and asset transactions of innovative drugs
Professional Insights: Understanding the Development Direction of Overseas Expansion
During the conference, Mr. Ken Chen, Vice President of Clinical Service Center, was invited to host the session on "Overseas Market Layout & Asset Transactions for Innovative Drugs." The session invited Mr. Chen Dadong, Managing Director of BFC Group; Mr. Tong Peirong, Vice President of BD at Nianyan Pharmaceutical; and Ms. Tong Ling, Deputy General Manager of Beijing Buchang New Drug Research and Development Co., Ltd. They discussed the current status and prospects of overseas asset transactions for Chinese pharmaceutical companies, end-to-beginning project development strategies based on overseas market layouts, and global asset transaction strategies from the perspective of biopharmaceutical companies.
In the special session, Mr. Ken Chen, Vice President of Clinical Service Center, provided in-depth insights into the current status and prospects of overseas asset transactions for Chinese pharmaceutical companies. He discussed how, in the face of a capital winter, innovative biopharmaceutical companies are preparing to go global with varying strategies. These include joint ventures, leveraging existing platforms, and independent ventures:
Joint Ventures: The advantage is reducing local policy barriers and accelerating product entry. The disadvantage lies in managing cross-cultural communication and coordination issues.
Leveraging Existing Platforms: This approach is flexible and efficient, with lower investment requirements for Chinese pharmaceutical companies and relatively lower entry barriers compared to mainstream innovative drug global expansion models. However, the downside is the loss of future R&D and commercialization rights in the overseas market, limiting the company's potential gains.
Independent Ventures: This strategy allows for greater autonomy in R&D, commercialization, and supply chain choices, benefiting Chinese pharmaceutical companies in strengthening their global presence in the innovative drug sector. However, it requires the company to face global competition, necessitating higher innovation, R&D capabilities, strategic management, and cross-border coordination skills. Additionally, it involves more challenging communications with local government departments and demands substantial financial support from the company.
The most successful global expansion strategy among Asian enterprises is exemplified by Takeda. With a history of nearly 80 years of international ventures, Takeda has achieved global presence through various models, including joint ventures with Abbott to establish laboratories, corporate acquisitions, and in-licensing products. Over the span of a century, Takeda has become one of the top 10 pharmaceutical companies worldwide. Every company aspiring to go global should study Takeda's journey in-depth.
China's pharmaceutical industry is rapidly advancing, particularly achieving significant milestones in the field of innovative drugs. As the global pharmaceutical market continues to expand, Chinese innovative drugs are gradually moving towards international markets, creating a strong wave of internationalization. This trend not only constitutes a vital component of Chinese pharmaceutical companies' globalization strategies but also signifies a significant enhancement in the international competitiveness of China's pharmaceutical industry.